

Special Issue

Advances in Cancer Cachexia

Message from the Guest Editors

In this Special Issue of *Cancers*, we aim to publish a collection of manuscripts that further our understanding of cancer cachexia and provide novel approaches of assessing cachexia severity, thereby advancing our insights into the factors that play a role in its development and enabling clinical trials with better cachexia phenotyping. In particular, we are looking for papers that describe:

- Development of novel translational models of cancer cachexia (e.g., organoids or new mouse models with slower cachexia progression);
- The role of inflammation and immune cell activation in cancer cachexia;
- The role of the liver and of insulin resistance in cancer cachexia;
- Myosteatosis and other body composition changes in patients with cancer cachexia;
- Artificial intelligence-based approaches to body composition analysis;
- Use of wearables to assess cachexia severity;
- Relationship between body composition and immunotherapy outcomes;
- Prehabilitation approaches to improve therapeutic outcome of cachectic patients.

Guest Editors

Dr. Sander S. Rensen
Prof. Dr. Steven W. M. Olde Damink
Dr. David P.J. Van Dijk

Deadline for manuscript submissions

closed (31 January 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/140006

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)